Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures

Trial Profile

Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2014

At a glance

  • Drugs Eslicarbazepine acetate (Primary)
  • Indications Partial epilepsies
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 Jul 2014 According to a Bial media release, eslicarbazepine acetate was approved in Europe on the basis of efficacy and safety data from this and four other phase III trials (see profiles 70037569, 70037570, 70037571 and 70049692.)
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top